Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.
The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose- and concentration-response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure-response relationships early on.
Tabrizi
Mohammad
M
AnaptysBio, Inc., San Diego, California 92121, USA. mtabrizi@anaptysbio.com
Funelas
Cherryl
C
Suria
Hamza
H
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007118:Immunoassay
D000911:Antibodies, Monoclonal